Clinical trials: MTOR
Advanced Refractory Solid Tumors
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in…
- Trial name
- NCT01762410
- Testing
- P7170
- Where
- 4 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Piramal Enterprises Limited
Advanced Breast Cancer
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR…
- Trial name
- NCT07173556
- Testing
- QLC1401
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Prostate cancer is a common and important health issue. Although effective treatment is often available for localized disease, metastatic prostate cancer remains incurable.
- Trial name
- NCT00574769
- Testing
- RAD001, Docetaxel, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Well-differentiated Neuroendocrine Tumors
A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
Neuroendocrine tumors are rare but recent data showed a relevant increase in its incidence. The Mammalian Target of Rapamycin (mTOR), one of most important area of research, has demonstrated be a therapeutic target in these…
- Trial name
- MetNet (NCT02279758)
- Testing
- Metformin
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Neoplasm Metastases
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer.
- Trial name
- NCT01122199
- Testing
- RAD001 + AMG479
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Shadia Jalal
Solid Tumors
A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
Background: The PI3K/Akt/mTOR pathway is an important target in cancer because it promotes chemotherapeutic resistance and confers a poor prognosis for many types of cancers.
- Trial name
- NCT01445106
- Testing
- Nelfinavir, Nelfinavir Mesylate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Epilepsy, Tuberous Sclerosis Complex
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
The goal of this study is to learn if the study drug RAD001 can reduced the number of epileptic seizures, and can be taken safety by people who have epilepsy associated with Tuberous Sclerosis Complex.
- Trial name
- NCT01070316
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Renal Cancer, Birt-Hogg-Dube Syndrome
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Background: Research has shown that the drug everolimus can stop cancer cells from growing. It is approved for people with advanced kidney cancer.
- Trial name
- NCT02504892
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Everolimus, Pneumonitis
Everolimus Related Pneumonitis in MBC
To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.
- Trial name
- NCT03730428
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Fudan University
Breast Cancer
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after progression on trastuzumab are enrolled and…
- Trial name
- NCT04736589
- Testing
- Inetetamab, Rapamycin, Pyrotinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking Union Medical College
Advanced Cancers
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of sirolimus or vorinostat that can be given in combination with hydroxychloroquine to patients with advanced cancer.
- Trial name
- NCT01266057
- Testing
- Hydroxychloroquine, Sirolimus, Vorinostat
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
This is a dose-escalation Phase Ib clinical trial in 18 patients with newly diagnosed Stage I-IV ER+/HER2- breast cancer, with the primary cancer in place.
- Trial name
- NCT02626507
- Testing
- Gedatolisib, Faslodex, Palbociclib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoffman Oncology
Colorectal Cancer
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may increase efficacy for patients with metastatic colorectal cancer who progressed on prior chemotherapy.
- Trial name
- NCT00522665
- Testing
- Irinotecan, Cetuximab, RAD001
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoosier Cancer Research Network
Liver Allograft, Liver Diseases
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
- Conditions
- Liver Allograft, Liver Diseases, Liver Transplantation
- Trial name
- ALTERNATION (NCT07739914)
- Testing
- Everolimus, Tacrolimus or Cyclosporine
- Where
- 16 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Hannover Medical School
Neuroblastoma Recurrent
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
Children, adolescents and young adults with high risk relapsed or treatment refractory neuroblastoma (rNB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not…
- Trial name
- RIST-rNB-2011 (NCT01467986)
- Testing
- Dasatinib, Rapamycin, Irinotecan
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University of Regensburg
Activated PI3K-delta Syndrome, Immunodeficiency Primary
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).
- Trial name
- NCT03383380
- Testing
- Rapamycin
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Fudan University
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.
- Trial name
- NCT03433183
- Testing
- Selumetinib, Sirolimus
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Gastrointestinal Neoplasms
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
The underlying hypothesis of the synergistic activity of octreotide and everolimus is based on the combination of a) a direct action of everolimus over mTOR (mammalian target of rapamycin), and b) the inhibitory effect of…
- Trial name
- EVERLAR (NCT01567488)
- Testing
- Everolimus, octreotide LAR
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, NET
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with…
- Conditions
- Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NCT05997056
- Testing
- nab-sirolimus
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aadi Bioscience, Inc.